Advertisement
IQV vs TMO
Which Stock Would AI Choose? IQVIA Holdings (IQV) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- IQV and TMO operate in adjacent healthcare segments, with IQV focused on clinical research and analytics while TMO emphasizes life sciences instruments and diagnostics.
- Both stocks delivered solid first-quarter 2026 results, with IQV reporting 8.4% revenue growth and TMO posting 6% revenue growth, each beating analyst expectations.
- Recent market activity shows IQV trading near $206 with year-to-date returns around 8.5%, while TMO trades near $532 with year-to-date returns around 7.9%.
- Upcoming second-quarter 2026 earnings releases—TMO on July 23 and IQV on July 28—represent key near-term catalysts for both companies.
- IQV offers higher exposure to outsourced clinical services and data analytics, whereas TMO benefits from recurring revenue in laboratory and research tools amid broader life sciences spending.
- Relative performance over the past year has been comparable, with both names posting gains above the broader market benchmark.
Introduction
Investors and traders often compare IQV and TMO due to their overlapping yet distinct roles within the healthcare and life sciences ecosystem. IQV provides clinical research services, commercial insights, and healthcare intelligence primarily to pharmaceutical and biotech firms, while TMO supplies analytical instruments, reagents, and laboratory equipment essential for research and diagnostics. This comparison appeals to those seeking exposure to healthcare innovation and outsourcing trends, particularly portfolio managers evaluating sector allocation, growth-oriented investors monitoring earnings momentum, and traders assessing relative strength ahead of quarterly reports. The analysis focuses on verifiable recent performance and positioning without forward projections.
IQV Overview and Recent Performance
IQV (IQVIA Holdings Inc.) delivers clinical research services, data analytics, and commercial solutions to the life sciences industry. In recent weeks, the stock has traded near $206 amid broader healthcare sector activity. First-quarter 2026 results showed revenue of $4.151 billion, an 8.4% year-over-year increase, with adjusted diluted earnings per share of $2.90, exceeding estimates. Management raised full-year adjusted EPS guidance while reaffirming revenue targets, supported by share repurchases totaling $552 million in the quarter. Market sentiment has reflected steady interest in clinical outsourcing trends, with the shares posting year-to-date returns of approximately 8.5% and one-year returns near 26%. Upcoming second-quarter results, scheduled for July 28, 2026, represent the next focal point for performance evaluation.
TMO Overview and Recent Performance
TMO (Thermo Fisher Scientific Inc.) provides life sciences solutions, including analytical instruments, laboratory equipment, and diagnostics products. In recent market activity, the stock has traded near $532. First-quarter 2026 revenue reached $11.01 billion, up 6% year-over-year, with adjusted earnings per share of $5.44, surpassing consensus estimates. The company authorized a quarterly dividend of $0.47 per share, payable in October 2026. Year-to-date returns stand around 7.9%, with one-year returns near 25.75%. Recent sentiment has been influenced by sustained demand for research tools and preparations for second-quarter earnings on July 23, 2026, which analysts project at $11.68 billion in revenue.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed to navigate thousands of tickers across varied market conditions. Tickeron maintains hundreds of AI Trading Bots employing diverse trading styles, strategies, timeframes, and performance metrics tailored to different risk profiles and market environments. Only the strongest and most relevant bots for prevailing conditions earn placement in the Trending section, where users can review detailed statistics such as annualized returns ranging from 116% to 830% in backtesting, pattern detection accuracy between 85% and 92% for shorter-interval agents, and metrics including Sharpe ratios and profit factors. All bots differ in their approaches, from single-asset signals to multi-agent and hedged strategies. For further details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
IQV and TMO differ in business models: IQV centers on outsourced clinical trials, data analytics, and commercial services, creating exposure to pharmaceutical R&D spending cycles, while TMO focuses on high-margin instruments and consumables with more recurring revenue characteristics. Growth drivers contrast as well, with IQV benefiting from clinical trial outsourcing trends and TMO from laboratory infrastructure investments. Recent momentum appears balanced, with both names delivering earnings beats in the first quarter and comparable one-year returns. Risk factors include regulatory and biotech funding sensitivities for IQV versus supply chain and capital expenditure cycles for TMO. Sector exposure overlaps in healthcare but diverges in services versus tools, influencing relative positioning amid shifting investor preferences for services versus equipment providers.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent earnings delivery, stability of guidance updates, and relative sector positioning, Tickeron’s AI would currently assign a modest probabilistic edge to IQV over TMO for short-term momentum consideration, driven by stronger reported organic growth and raised EPS targets. However, outcomes remain contingent on upcoming quarterly results and broader market conditions, with neither stock demonstrating clear dominance across all evaluated metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 6 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- IQV’s TA Score: 6 bullish, 3 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а +0.87% price change this week, while TMO (@Medical Specialties) price change was +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | TMO | IQV / TMO | |
| Capitalization | 34.7B | 211B | 16% |
| EBITDA | 3.52B | 11.7B | 30% |
| Gain YTD | -7.702 | -1.736 | 444% |
| P/E Ratio | 25.84 | 30.58 | 85% |
| Revenue | 16.6B | 45.2B | 37% |
| Total Cash | 2.1B | 1.12B | 188% |
| Total Debt | 16.1B | 43.2B | 37% |
IQV | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 42 | 62 | |
PRICE GROWTH RATING 1..100 | 41 | 40 | |
P/E GROWTH RATING 1..100 | 62 | 37 | |
SEASONALITY SCORE 1..100 | 65 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is somewhat better than the same rating for IQV (65) in the Servicestothe Health Industry industry. This means that TMO’s stock grew somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (62) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
TMO's Price Growth Rating (40) in the Medical Specialties industry is in the same range as IQV (41) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as IQV (62) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
| IQV | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 50% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 61% |
| Advances ODDS (%) | 2 days ago 60% | 3 days ago 61% |
| Declines ODDS (%) | 4 days ago 65% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 57% | 2 days ago 59% |
Advertisement